Erlonat – Erlotinib Tablet
Description
ERLOTINIB (ERLONAT) TABLET – TREATMENT FOR MULTIPLE CANCER
Pancreatic and non-small cell lung cancer are both treated with Erlonat 150 Tablet.
Erlonat 150 Tablet should be consumed on an empty stomach, one hour prior to, or two hours following a meal. As long as your doctor recommends it, you should keep taking it. Depending on your needs and how you respond to treatment, the length of treatment varies.
Fedelty Health Care is an Erlotinib wholesaler, Pharmaceutical Cargo Bulk Exporter & Hospital Supply.
USES OF ERLOTINIB (ERLONAT) TABLET
- Non-small cell lung cancer
- Pancreatic cancer
WORKS OF ERLOTINIB (ERLONAT) TABLET
Erlonat 150 Tablet is a cancer preventative drug. Lung cancer cells have EGFRs expressed on their surfaces, which control how quickly they develop. This medication inhibits the EGFR-mediated cancer signaling pathways by binding to the chemical messenger EGFR. This is how it prevents the cancer cells from proliferating further.
Fedelty Health Care is an Erlotinib wholesaler, Pharmaceutical Cargo Bulk Exporter & Hospital Supply.
SIDE EFFECTS OF ERLOTINIB (ERLONAT) TABLET
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
WARNING & PRECAUTIONS
- Driving
The ability to drive may be affected by Erlonat 150 Tablet, however, this is unknown. If you encounter any symptoms that impair your focus or reaction time, avoid operating a vehicle.
- Kidney
Patients with kidney conditions can use Erlonat 150 Tablets without risk. It is not advised to change the dosage of Erlonat 150 Tablet.
Patients with severe kidney problems are not advised to use this medication.
- Liver
Patients with liver conditions should use Erlonat 150 Tablet with caution. There may need to be a dosage change for Erlonat 150 Tablet. Please speak with your physician.
On the use of Erlonat 150 Tablet in these patients, there is not much information available. In patients with mild to severe liver disease, there is no need to change the dosage.
Fedelty Health Care is an Erlotinib third-party manufacturer, bulk pharma exporter, and pharmaceutical contract manufacturer operating businesses in Venezuela, Saudi Arabia, Cambodia, Oman, Brazil, Lebanon, Chile, Peru, Cuba, and Fiji. Other services they provide are hospital supply, government supply, named patient supply, cold chain supply, and drop shipping.
